Company intelligence / Profile preview

Orphalan

Paris, Île-de-France, Franceorphalan.com ↗

Ownership: Private
Employees: ~125
Development stage: Other

Overview

Orphalan has successfully developed and commercialized trientine tetrahydrochloride as a treatment for Wilson disease. The drug has been approved in over 20 countries under various brand names. Clinical data from the pivotal Phase 3 CHELATE trial supported regulatory approvals. The company continues to innovate with new formulations to improve adherence and patient outcomes, as well as developing novel assays to measure treatment effectiveness.

Adherence challenges remain a key area of research focus.

Expansion into China marks significant global reach.

Therapeutic areas: Rare Diseases
Modalities: Small molecules (notably trientine tetrahydrochloride for Wilson disease)
Industry: Biotech

Drug pipeline

3 assets

trientine tetrahydrochloride

Approved

2 more assets in the full pipeline.

Partnerships

SPH Kyuan Trade Co., Ltd. (for commercialization/distribution in China)

Beyond the preview

Go deeper on Orphalan.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Orphalan.